European Companies Search Engine
EU funding (€3,969,936): AGE-RELATED CHANGES IN HEMATOPOIESIS Hor1 Jun 2019 EU Research and Innovation programme "Horizon"
Text
AGE-RELATED CHANGES IN HEMATOPOIESIS
ARCH is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific age-related hematological diseases (pediatric, adult, elderly), with the aim to develop novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and it will deploy a large panel of cutting-edge technologies, such as single cells genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 5 Partner organisations (3 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their italian nodes. ARCH will recruit 15 ESRs that will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. This broad portfolio will enable ESRs to become leading academic, clinic or industrial players in the field. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.
Funded Companies:
| Company name | Funding amount |
| ? | |
| Academisch Ziekenhuis Groningen | €265,620 |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | €250,905 |
| Centre Europeen de Recherche en Biologie et Medecine | €274,802 |
| Diagenode | €256,320 |
| €261,500 | |
| €261,500 | |
| €243,018 | |
| Institut Curie | €274,802 |
| Institut National de la Sante et de la Recherche Medicale | €274,802 |
| King's College London | €303,173 |
| MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN e. V. | €252,788 |
| €263,501 | |
| Universita Degli Studi DI Roma LA Sapienza | €261,500 |
| Universita' Degli Studi DI Milano-Bicocca | €261,500 |
| Veterinaermedizinische Universitaet Wien | €264,207 |
Source: https://cordis.europa.eu/project/id/813091
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Becton Dickinson Italia S.p.A., Castano Primo, Italy.
The visualizations for "Becton Dickinson Italia S.p.A. - EU funding (€3,969,936): AGE-RELATED CHANGES IN HEMATOPOIESIS"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
